BioNTech Balance Sheet Health
Financial Health criteria checks 6/6
BioNTech has a total shareholder equity of €20.2B and total debt of €2.4M, which brings its debt-to-equity ratio to 0.01%. Its total assets and total liabilities are €23.0B and €2.8B respectively. BioNTech's EBIT is €969.6M making its interest coverage ratio -2.7. It has cash and short-term investments of €16.5B.
Key information
0.01%
Debt to equity ratio
€2.40m
Debt
| Interest coverage ratio | -2.7x |
| Cash | €16.55b |
| Equity | €20.25b |
| Total liabilities | €2.76b |
| Total assets | €23.01b |
Recent financial health updates
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Apr 22
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Dec 11BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet
Sep 11Is BioNTech (NASDAQ:BNTX) A Risky Investment?
Jun 13These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely
Mar 05BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly
Nov 09Recent updates
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Apr 22We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings
Mar 27BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 24BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions
Mar 20BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time
Feb 23BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate
Feb 09Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%
Jan 18Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price
Jan 02BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Dec 11Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook
Oct 22BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet
Sep 11Is BioNTech (NASDAQ:BNTX) A Risky Investment?
Jun 13A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)
May 23BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates
Mar 29These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely
Mar 05A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)
Feb 18Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates
Feb 02With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case
Jan 26BioNTech SE (NASDAQ:BNTX) Held Back By Insufficient Growth Even After Shares Climb 36%
Nov 19BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly
Nov 09CDC advisory panel recommends COVID vaccines for children be included in federal program
Oct 19Do BioNTech's (NASDAQ:BNTX) Earnings Warrant Your Attention?
Oct 18Hong Kong approves BioNTech COVID vaccine for infants
Oct 12EMA starts rolling review of Pfizer/BioNTech's Omicron-subvariant adapted shot for kids
Oct 03BioNTech: A Tale Of 2 Companies
Sep 20European drug regulator panel backs approval of Pfizer/BioNTech's Omicron-adapted shot
Sep 12CDC advisors to vote on COVID Omicron vaccines on Sept. 1
Aug 30Financial Position Analysis
Short Term Liabilities: BNTX's short term assets (€19.5B) exceed its short term liabilities (€2.1B).
Long Term Liabilities: BNTX's short term assets (€19.5B) exceed its long term liabilities (€689.9M).
Debt to Equity History and Analysis
Debt Level: BNTX has more cash than its total debt.
Reducing Debt: BNTX's debt to equity ratio has reduced from 2.1% to 0.01% over the past 5 years.
Debt Coverage: BNTX's debt is well covered by operating cash flow (223808.3%).
Interest Coverage: BNTX earns more interest than it pays, so coverage of interest payments is not a concern.